GBD has been delivering tailored quality control samples for laboratory medicine around the world for more than 30 years.
GBD - Gesellschaft für biotechnologische Diagnostik
GBD contributes to securing and improving the quality of laboratory diagnostics, thereby supporting the development of a stable healthcare system worldwide.
Our main focus is on producing quality control samples and reference materials for laboratory medicine, with a particular emphasis on viral diagnostics. By maintaining close communication with our clients and being part of a scientific network, we are able to identify technical, epidemiological, and diagnostic developments early on. We respond to these changes flexibly by providing tailored quality control samples and reference materials.
For more than 30 years, we have been active in this field. With our expertise, scientific dedication, and spirit of innovation, we are committed to both external and internal quality assurance in laboratory diagnostics. As a scientific institute and manufacturer, our team continuously advances both our knowledge and our products.
Our driving force is solving scientific challenges and strengthening laboratory medicine through our products. We set standards to ensure greater safety for everyone.
Focus topics
- Sustainable quality improvement
- Standardization of laboratory diagnostics
location
Berlin, Germany
Partner website
Sales region
Partner since
Founding year
ISO number
Our focuses:
- Production of internal and external quality control samples (including in viral diagnostics and bacterial genome detection)
- Production of reference materials and (secondary) standards for viral diagnostics
Case Studies
Explore how we to drive innovation, enhance solutions, and achieve impactful results across industries. Discover our success stories.
DailyCheck verification samples for syndromic testing
In collaboration with Seegene Germany, we have developed "DailyCheck" controls. These are verification samples designed for daily use in multiplex assays. The pathogen composition is specifically adapted to Seegene assays. Each sample contains up to seven pathogens, closely mimics real clinical material, and is both stable and easy to handle. These features allow laboratories to use them as cost-effective quality controls in syndromic testing. We recently had the opportunity to present our product during a Seegene-organized webinar attended by global distributors.
New Advances in dPCR Thanks to Expanded Partnership with Bio-Rad
GBD has extended its partnership with Bio-Rad for dPCR to further develop innovative technology that enables ultra-sensitive nucleic acid detection and absolute quantification. This fall, we will present our findings in lectures and share them with our network. Some control samples have already been analyzed using dPCR, and we plan to increasingly use quantified materials in the future. This brings us closer to our goal of contributing to standardization in laboratory diagnostics.
Collaboration with INSTAND e.V. Introduces Innovative Proficiency Testing Program
In collaboration with INSTAND e.V., we have planned and implemented a new proficiency testing program. With a single sample panel, laboratories can detect the genomes of up to 10 different STI pathogens – saving users both time and costs, while also providing valuable training for labs in this area. The program has been in high demand from our clients and will be shipped for the first time in October. We are pleased to have identified and met such an important need with this panel.